Early response of hepatic malignancies to locoregional therapy - Value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy

Journal of Computer Assisted Tomography

Volumn 35, Issue 2, 2011, Pages 167-173

  Bonekamp, Susanne ^a   Shen, Jialin ^b   Salibi, Nouha ^c   Lai, Hong C ^a   Geschwind, Jeff ^a   Kamel, Ihab R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

diffusion weighted imaging; liver cancer; magnetic resonance imaging; magnetic resonance spectroscopy

Indexed keywords

DISEASES; MAGNETISM; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT TREATMENT; SURFACE DIFFUSION; TUMORS;

AFTER-TREATMENT; APPARENT DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DIFFUSION-WEIGHTED MAGNETIC RESONANCE; EVALUATION CRITERIA; LIVER CANCERS; MEAN AGES; PROTON MAGNETIC RESONANCE SPECTROSCOPIES; SOLID TUMORS; TRANSARTERIAL CHEMOEMBOLIZATION;

MAGNETIC RESONANCE IMAGING;

ANTINEOPLASTIC AGENT; CHOLINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER SIZE; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; LIVER CANCER; LOCOREGIONAL THERAPY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79953824869     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3182004bfb     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
3. Varona MA, Del Pino JM, Barrera M, et al. Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc. 2009;41:1005-1008.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
5. Maluf D, Fisher RA, Maroney T, et al. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003;3:312-317. (Pubitemid 36407050)
6. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
7. Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2009;13:233-247.
8. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
10. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102-125.
11. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505-512. (Pubitemid 44318722)
12. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;181:708-710. (Pubitemid 37021839)
13. Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008;190:67-73.
14. Vossen JA, Buijs M, Liapi E, et al. Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions. J Comput Assist Tomogr. 2008;32:750-756.
15. Vossen JA, Kamel IR, Buijs M, et al. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008;32:347-352.
16. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol. 2006;17:1195-1200. (Pubitemid 44318703)
17. Yuan Z, Ye XD, Dong S, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol. 2009.
18. Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience. Radiology. 2006;239:448-456.
19. Marugami N, Tanaka T, Kitano S, et al. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Intervent Radiol. 2009;32:638-646.
20. Sardanelli F, Fausto A, Di Leo G, et al. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol. 2009;192:1608-1617.
21. Laprie A, Catalaa I, Cassol E, et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2008;70:773-781. (Pubitemid 351199728)
22. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63:351-360. (Pubitemid 47321931)
23. Lichy MP, Bachert P, Hamprecht F, et al. Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors. Rofo. 2006;178:627-633.
24. Li CW, Kuo YC, Chen CY, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med. 2005;53:770-776. (Pubitemid 40478423)
25. Pucar D, Koutcher JA, Shah A, et al. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer. 2004;3:174-181. (Pubitemid 40051709)
26. Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J. 2006;21:258-264.
27. Kuo YT, Li CW, Chen CY, et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 2004;19:598-604.
28. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623.
29. Mannelli L, Kim S, Hajdu CH, et al. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009;193:1044-1052.
30. 1H-MRS in the DEN-induced hepatocellular carcinoma in Wistar rat. J Cancer Res Clin Oncol. 2005;131:597-602.
31. Fischbach F, Schirmer T, Thormann M, et al. Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 tesla. Eur Radiol. 2008;18:2549-2558.
32. Bakken IJ, Gribbestad IS, Singstad TE, et al. External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 tesla. Magn Reson Med. 2001;46:189-192. (Pubitemid 32592153)
33. 1H MR spectroscopy. Magn Reson Med. 2003;50:1134-1143.
34. 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA. 2006;19:96-104.